These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 20026611

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation.
    Gershkovich P, Wasan EK, Lin M, Sivak O, Leon CG, Clement JG, Wasan KM.
    J Antimicrob Chemother; 2009 Jul; 64(1):101-8. PubMed ID: 19398459
    [Abstract] [Full Text] [Related]

  • 4. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation.
    Espada R, Valdespina S, Dea MA, Molero G, Ballesteros MP, Bolás F, Torrado JJ.
    J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313
    [Abstract] [Full Text] [Related]

  • 5. Pharmacodynamics and Biodistribution of Single-Dose Liposomal Amphotericin B at Different Stages of Experimental Visceral Leishmaniasis.
    Voak AA, Harris A, Qaiser Z, Croft SL, Seifert K.
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630200
    [Abstract] [Full Text] [Related]

  • 6. Novel oral amphotericin B formulation (iCo-010) remains highly effective against murine systemic candidiasis following exposure to tropical temperature.
    Wasan KM, Sivak O, Bartlett K, Wasan EK, Gershkovich P.
    Drug Dev Ind Pharm; 2015 Sep; 41(9):1425-30. PubMed ID: 25170660
    [Abstract] [Full Text] [Related]

  • 7. Highly effective oral amphotericin B formulation against murine visceral leishmaniasis.
    Wasan KM, Wasan EK, Gershkovich P, Zhu X, Tidwell RR, Werbovetz KA, Clement JG, Thornton SJ.
    J Infect Dis; 2009 Aug 01; 200(3):357-60. PubMed ID: 19545212
    [Abstract] [Full Text] [Related]

  • 8. Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome.
    Gangneux JP, Sulahian A, Garin YJ, Farinotti R, Derouin F.
    Antimicrob Agents Chemother; 1996 May 01; 40(5):1214-8. PubMed ID: 8723469
    [Abstract] [Full Text] [Related]

  • 9. A novel tropically stable oral amphotericin B formulation (iCo-010) exhibits efficacy against visceral Leishmaniasis in a murine model.
    Wasan EK, Gershkovich P, Zhao J, Zhu X, Werbovetz K, Tidwell RR, Clement JG, Thornton SJ, Wasan KM.
    PLoS Negl Trop Dis; 2010 Dec 07; 4(12):e913. PubMed ID: 21151883
    [Abstract] [Full Text] [Related]

  • 10. Biodistribution and In Vivo Antileishmanial Activity of 1,2-Distigmasterylhemisuccinoyl-sn-Glycero-3-Phosphocholine Liposome-Intercalated Amphotericin B.
    Iman M, Huang Z, Alavizadeh SH, Szoka FC, Jaafari MR.
    Antimicrob Agents Chemother; 2017 Sep 07; 61(9):. PubMed ID: 28630182
    [Abstract] [Full Text] [Related]

  • 11. Biodistribution and tissue toxicity of amphotericin B in mice following multiple dose administration of a novel oral lipid-based formulation (iCo-009).
    Gershkovich P, Sivak O, Wasan EK, Magil AB, Owen D, Clement JG, Wasan KM.
    J Antimicrob Chemother; 2010 Dec 07; 65(12):2610-3. PubMed ID: 20861140
    [Abstract] [Full Text] [Related]

  • 12. Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B.
    Smith PJ, Olson JA, Constable D, Schwartz J, Proffitt RT, Adler-Moore JP.
    J Antimicrob Chemother; 2007 May 07; 59(5):941-51. PubMed ID: 17400589
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of low doses of amphotericin B plus allicin against experimental visceral leishmaniasis.
    Corral MJ, Serrano DR, Moreno I, Torrado JJ, Domínguez M, Alunda JM.
    J Antimicrob Chemother; 2014 Dec 07; 69(12):3268-74. PubMed ID: 25096077
    [Abstract] [Full Text] [Related]

  • 14. Epidemiological, clinical & pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India.
    Thakur CP, Narayan S, Ranjan A.
    Indian J Med Res; 2004 Sep 07; 120(3):166-72. PubMed ID: 15489554
    [Abstract] [Full Text] [Related]

  • 15. Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres.
    Sánchez-Brunete JA, Dea MA, Rama S, Bolás F, Alunda JM, Raposo R, Méndez MT, Torrado-Santiago S, Torrado JJ.
    Antimicrob Agents Chemother; 2004 Sep 07; 48(9):3246-52. PubMed ID: 15328080
    [Abstract] [Full Text] [Related]

  • 16. Bioinspired Calcium Phosphate Nanoparticles Featuring as Efficient Carrier and Prompter for Macrophage Intervention in Experimental Leishmaniasis.
    Chaurasia M, Singh PK, Jaiswal AK, Kumar A, Pawar VK, Dube A, Paliwal SK, Chourasia MK.
    Pharm Res; 2016 Nov 07; 33(11):2617-29. PubMed ID: 27401407
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetic / pharmacodynamic relationships of liposomal amphotericin B and miltefosine in experimental visceral leishmaniasis.
    Voak AA, Harris A, Coteron-Lopez JM, Angulo-Barturen I, Ferrer-Bazaga S, Croft SL, Seifert K.
    PLoS Negl Trop Dis; 2021 Mar 07; 15(3):e0009013. PubMed ID: 33651812
    [Abstract] [Full Text] [Related]

  • 18. Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans.
    van Etten EW, Otte-Lambillion M, van Vianen W, ten Kate MT, Bakker-Woudenberg AJ.
    J Antimicrob Chemother; 1995 Apr 07; 35(4):509-19. PubMed ID: 7628985
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis.
    Syriopoulou V, Daikos GL, Theodoridou M, Pavlopoulou I, Manolaki AG, Sereti E, Karamboula A, Papathanasiou D, Krikos X, Saroglou G.
    Clin Infect Dis; 2003 Mar 01; 36(5):560-6. PubMed ID: 12594635
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.